The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

A pair of FDA-approved cancer drugs may help reverse the biological changes that drive Alzheimer’s disease, according to a ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Alzheimer’s, the most common form of dementia, is one of the leading causes of death in western countries such as the UK. But current medicines can only slightly alleviate the symptoms, of ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They found that the drug slowed cognitive decline by 46% in a group of ...

Scientists have used AI to re-analyse a clinical trial for an Alzheimer’s medicine, and identified a group of patients who responded to treatment. The work demonstrates that AI can inform the design ...